title: Recombinant erythropoietin and analogues: a challenge for doping control.
abstract: Erythropoietin (EPO) increases the number of circulating erythrocytes and thus muscle oxygenation. The availability of the recombinant protein (rEPO) has increased the risk of its illegal use in sports, its detection being a difficult challenge. Five different hematopoietic parameters were initially chosen as indirect markers of rEPO abuse: concentration of serum EPO, concentration of serum-soluble transferrin receptors (sTFr), hematocrit, percentage of reticulocytes, and percentage of macrocytes. New models considering only hemoglobin, serum EPO concentration, and percentage of reticulocytes are simpler and seem to be more sensitive when low doses of rEPO are used. A more direct method of urine analysis (isoelectrofocusing, double blotting, and chemiluminescent detection) based on the charge differences between rEPO and endogenous EPO, related to their carbohydrate composition, provides proof of rEPO use. Furthermore, this approach permits the detection of darbepoetin, a direct analogue of EPO also known as NESP ("new erythropoiesis stimulating protein"). Recently a protein conjugate, "synthetic erythropoiesis protein" (SEP), containing precision-length, monodisperse, negatively charged polymers instead of oligosaccharides has been synthesized. Finally, EPO-mimetics are molecules capable of acting as EPO in dimerizing the EPO receptor. Two kinds of EPO-mimetics have been described: peptides and nonpeptides. The enhancement of oxygen availability to muscles by rEPO, analogues, and mimetics constitutes one of the main challenges to doping control. Major steps have already been developed for detection ofrEPO and some analogues. In the near future, the transfection to an athlete's body of genes that code for erythropoietin might be an emerging doping issue, and sports authorities have incorporated "gene doping" among the prohibited practices.
authors.affiliation: Drug Research Unit, Municipal Institute of Medical Research, IMIM, Barcelona, Spain. jap@imim.es
authors.forename: J A
authors.initials: JA
authors.lastname: Pascual
authors.forename: V
authors.initials: V
authors.lastname: Belalcazar
authors.forename: C
authors.initials: C
authors.lastname: de Bolos
authors.forename: R
authors.initials: R
authors.lastname: Gutiérrez
authors.forename: E
authors.initials: E
authors.lastname: Llop
authors.forename: J
authors.initials: J
authors.lastname: Segura
mesh_terms: D015415:Biomarkers / Q000032:analysis; D004300:Doping in Sports / Q000379:methods / Q000517:prevention & control* / Q000639:trends; D004921:Erythropoietin / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000494:pharmacology; D015316:Genetic Therapy; D006801:Humans; D011994:Recombinant Proteins; D015813:Substance Abuse Detection / Q000379:methods*; D014162:Transfection
chemical_list: D015415:Biomarkers; D011994:Recombinant Proteins; D004921:Erythropoietin